New hope for rare lung cancer mutations: dacomitinib trial underway
NCT ID NCT04504071
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 36 times
Summary
This phase 2 trial tests the drug dacomitinib in 30 people with advanced non-small cell lung cancer that has uncommon EGFR mutations. Participants take a daily pill until their disease worsens or side effects become too much. The main goal is to see how many patients' tumors shrink, with secondary goals of controlling disease and delaying progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER METASTATIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Shanghai Chest hospital
Shanghai, Shanghai Municipality, 200030, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dacomitinib (a targeted cancer pill)
What this could lead to
If successful, this could provide a new treatment option for people with advanced lung cancer who have rare EGFR mutations.
What could go wrong
This is a small, early-phase study with only 30 participants, so results may not apply to everyone. The drug may cause side effects or stop working over time.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.